Menkes Disease Epidemiology Forecast

DelveInsight’s ‘Menkes Disease- Epidemiology Forecast– 2032’ report delivers an in-depth understanding of the Menkes Disease, historical and forecasted epidemiology as well as the Menkes Disease epidemiology trends in the G11 i.e. United States, EU-5 (Germany, France, Italy, Spain, and the United Kingdom), Japan, Australia, New Zealand, China, and South Korea.

Geographies Covered

  • The United States
  • EU5 (Germany, France, Italy, Spain, and the United Kingdom)
  • Japan
  • Australia
  • New Zealand
  • China
  • South Korea

Study Period: 2019–2032

Menkes Disease Disease Understanding

Menkes disease (MD) is a lethal infantile neurodegenerative disorder with X-linked inheritance. It is an inherited X-linked recessive disorder caused by mutations in the ATP7A gene that is responsible for the transport of copper throughout the body. The mutation could lead to premature birth and may have non-specific symptoms such as hypothermia, hypoglycemia, and prolonged jaundice. These non-specific clinical and biochemical findings could result in the misdiagnosis of neonatal Menkes disease.

 

Menkes disease is usually inherited, which means it runs in families. The gene is on the X-chromosome, so if a mother carries the defective gene, each of her sons has a 50% (1 in 2) chance of developing the disease, and 50% of her daughters will be a carrier of the disease. The symptoms may not appear in infants until two to three months after birth.

 

Symptoms of Menkes disease begin shortly after birth and may vary from person to person. The typical symptoms usually start by two months with characteristic skin and hair findings. Sagging facial features, micrognathia, cutis laxa, and blue iris can be noted. Congenital malformations have been reported, including congenital microblepharia, entropion, long arched palate, cerebellar hypoplasia, cystic changes in the lungs, and complete AV block. Neurological manifestations are the most common and characteristic of Menkes disease. Developmental regression and seizures are usually the first to start around 2–3 months.

 

Menkes Disease Diagnosis

Initial diagnosis is based on clinical features (typical hair changes associated with hypotonia and delayed neuromotor development) and supported by the demonstration of reduced levels of serum copper and ceruloplasmin.

 

Prenatal diagnosis can be possible where the pathogenic variant has a history in the family and it is a preferred test to determine the carrier status of the mother before pregnancy.

Continued in the report…..

Menkes Disease Epidemiology Perspective by DelveInsight

The disease epidemiology covered in the report provides historical as well as forecasted epidemiology segmented by total diagnosed prevalent cases of Menkes disease in the G11 covering the United States, EU-5 (Germany, France, Italy, Spain, and the United Kingdom), Japan, Australia, New Zealand, China, and South Korea from 2019 to 2032.

Menkes Disease Detailed Epidemiology Segmentation

  • As per the assessment of DelveInsight, the total diagnosed prevalent cases of Menkes Disease in the G11 were found to be 265 in 2021, which are expected to increase at a Compound Annual Growth Rate (CAGR) of 6.12% during the study period.
  • Among G11, the United States had 79 diagnosed prevalent cases of Menkes Disease in 2021, which was equivalent to 30% of the total diagnosed prevalent cases in G11.
  • In 2021, the EU-5 accounted for 57 diagnosed prevalent cases of Menkes Disease, which will increase by 2032 at a CAGR of 5.97%.
  • Among the European countries, France had the highest diagnosed prevalent population of Menkes Disease with 15 cases, followed by Germany and UK with 14 cases in each country, in 2021. On the other hand, Spain had the lowest diagnosed prevalent population.
  • In 2021, Japan had 19 diagnosed cases of Menkes Disease. These cases are expected to increase by 2032 at a CAGR of 4.76% during the forecasted period (2022–2032).
  • In South Korea, 8 cases of Menkes Disease were estimated, in 2021.
  • China accounted highest diagnosed prevalent cases of Menkes Disease with 81 cases in 2021, in G11.

Scope of the Report

  • The report covers the descriptive overview of Menkes Disease, explaining its symptoms, etiology, pathogenesis, and various diagnostic approaches.
  • The report provides insight into the G11 historical and forecasted patient pool.
  • The report assesses the disease risk and burden of Menkes Disease.
  • The report helps to recognize the growth opportunities in the G11 with respect to the patient population.
  • The report provides the segmentation of the disease epidemiology for G11 total diagnosed prevalent cases of Menkes Disease.

Report Highlights

  • 11-Year Forecast of Menkes Disease
  • G11 Coverage
  • Diagnosed Prevalent Cases of Menkes Disease

Key Questions Answered

  • What are the disease risk and burdens of Menkes Disease?
  • What is the historical Menkes Disease patient pool in the G11?
  • What would be the forecasted patient pool of Menkes Disease at the G11 level?
  • What will be the growth opportunities across the G11 with respect to the patient population pertaining to Menkes Disease?
  • Out of the above-mentioned countries, which country would have the highest patient population of Menkes Disease during the forecast period (2022–2032)?
  • At what CAGR the population is expected to grow across the G11 during the forecast period (2022–2032)?

Reasons to buy

The Menkes Disease report will allow the user to -

  • Develop business strategies by understanding the trends shaping and driving the G11 Menkes Disease epidemiology forecast.
  • The Menkes Disease epidemiology report and model were written and developed by Masters and Ph.D. level epidemiologists.
  • The Menkes Disease epidemiology model developed by DelveInsight is easy to navigate, interactive with dashboards, and epidemiology based on transparent and consistent methodologies. Moreover, the model supports data presented in the report and showcases disease trends over the 11-year forecast period using reputable sources.

Key Assessments

  • Patient Segmentation
  • Disease Risk and Burden
  • Risk of disease by the segmentation
  • Factors driving growth in a specific patient population

1. Key Insights

2. Report Introduction

3. Menkes Disease Epidemiology Overview at a Glance

3.1. Patient Share (%) Distribution of Menkes Disease in 2019

3.2. Patient Share (%) Distribution of Menkes Disease in 2032

4. Executive Summary of Menkes Disease

5. Disease Background and Overview: Menkes Disease

5.1. Introduction of Menkes Disease

5.2. Etiology of Menkes Disease

5.3. Signs and Symptoms of Menkes Disease

5.4. Pathophysiology of Menkes Disease

5.5. Differential Diagnosis

5.6. Diagnosis of Menkes Disease

5.6.1. Diagnosis Algorithm

5.6.1.1. Diagnosis Recommendation

6. Epidemiology and Patient Population

6.1. Key Findings

6.2. Methodology of Epidemiology

6.3. Assumptions and Rationale: G11

6.3.1. The United States

6.3.2. The Five European Countries (Germany, France, Italy, Spain, and the United Kingdom)

6.3.3. Japan

6.3.4. Australia

6.3.5. New Zealand

6.3.6. China

6.3.7. South Korea

6.4. Total Diagnosed Prevalent Cases of Menkes Disease in the G11

6.5. The United States

6.5.1. Diagnosed Prevalent Cases of Menkes Disease in the United States

6.6. Five Major European Countries (Germany, France, Italy, Spain, and the United Kingdom)

6.6.1. Germany

6.6.1.1. Diagnosed Prevalent Cases of Menkes Disease in Germany

6.6.2. France

6.6.2.1. Diagnosed Prevalent Cases of Menkes Disease in France

6.6.3. Italy

6.6.3.1. Diagnosed Prevalent Cases of Menkes Disease in Italy

6.6.4. Spain

6.6.4.1. Diagnosed Prevalent Cases of Menkes Disease in Spain

6.6.5. United Kingdom

6.6.5.1. Diagnosed Prevalent Cases of Menkes Disease in United Kingdom

6.7. Japan

6.7.1. Diagnosed Prevalent Cases of Menkes Disease in Japan

6.8. Australia

6.8.1. Diagnosed Prevalent Cases of Menkes Disease in Australia

6.9. New Zealand

6.9.1. Diagnosed Prevalent Cases of Menkes Disease in New Zealand

6.10. China

6.10.1. Diagnosed Prevalent Cases of Menkes Disease in China

6.11. South Korea

6.11.1. Diagnosed Prevalent Cases of Menkes Disease in South Korea

7. Patient Journey

8. KOL Views

9. Appendix

9.1. Bibliography

9.2. Report Methodology

10. DelveInsight Capabilities

11. Disclaimer

12. About DelveInsight

List of Table

Table 1: Summary of Menkes Disease Epidemiology (2019–2032)

Table 2: Disease background

Table 3: Diagnosed Prevalent Cases of Menkes Disease in the G11 (2019–2032)

Table 4: Diagnosed Prevalent Cases of Menkes Disease in the US (2019–2032)

Table 5: Diagnosed Prevalent Cases of Menkes Disease in EU-5 (2019–2032)

Table 6: Diagnosed Prevalent Cases of Menkes Disease in Germany (2019–2032)

Table 7: Diagnosed Prevalent Cases of Menkes Disease in France (2019–2032)

Table 8: Diagnosed Prevalent Cases of Menkes Disease in Italy (2019–2032)

Table 9: Diagnosed Prevalent Cases of Menkes Disease in Spain (2019–2032)

Table 10: Diagnosed Prevalent Cases of Menkes Disease in the United Kingdom (2019–2032)

Table 11: Diagnosed Prevalent Cases of Menkes Disease in Japan (2019–2032)

Table 12: Diagnosed Prevalent Cases of Menkes Disease in Australia (2019–2032)

Table 13: Diagnosed Prevalent Cases of Menkes Disease in New Zealand (2019–2032)

Table 14: Diagnosed Prevalent Cases of Menkes Disease in China (2019–2032)

Table 15: Diagnosed Prevalent Cases of Menkes Disease in South Korea (2019–2032)

List of Figures

Figure 1: X-linked recessive inheritance pattern

Figure 2: Signs and Symptoms of Menkes Disease

Figure 3: MRI Brain (T2W axial view)

Figure 4: Early diagnosis of Menkes Disease

Figure 5: Diagnosed Prevalent Cases of Menkes Disease in the G11 (2019–2032)

Figure 6: Diagnosed Prevalent Cases of Menkes Disease in the US (2019–2032)

Figure 7: Diagnosed Prevalent Cases of Menkes Disease in EU-5 (2019–2032)

Figure 8: Diagnosed Prevalent Cases of Menkes Disease in Germany (2019–2032)

Figure 9: Diagnosed Prevalent Cases of Menkes Disease in France (2019–2032)

Figure 10: Diagnosed Prevalent Cases of Menkes Disease in Italy (2019–2032)

Figure 11: Diagnosed Prevalent Cases of Menkes Disease in Spain (2019–2032)

Figure 12: Diagnosed Prevalent Cases of Menkes Disease in the United Kingdom (2019–2032)

Figure 13: Diagnosed Prevalent Cases of Menkes Disease in Japan (2019–2032)

Figure 14: Diagnosed Prevalent Cases of Menkes Disease in Australia (2019–2032)

Figure 15: Diagnosed Prevalent Cases of Menkes Disease in New Zealand (2019–2032)

Figure 16: Diagnosed Prevalent Cases of Menkes Disease in China (2019–2032)

Figure 17: Diagnosed Prevalent Cases of Menkes Disease in South Korea (2019–2032)

Figure 18: Patient Journey

Forward to Friend

Need A Quote